Based on the above findings, we propose that DDX17 is a valuable predictor of metastasis risk and prognosis for CRC patients, and the assessment of DDX17 expression may be beneficial for the development of a personalized therapeutic strategy. The gene discussed is DDX17; the disease is colorectal carcinoma.